CorMedix (CRMD) Net Equity Issued and Repurchased (2015 - 2025)

CorMedix has reported Net Equity Issued and Repurchased for 11 years, with the latest figure at $1.0 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased fell 81.36% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (down 57.46% YoY) and the FY2025 annual result came in at $7.8 million, down 58.75% from the prior year.
• Net Equity Issued and Repurchased eased to $1.0 million in Q4 2025 per CRMD's latest filing, from $6.8 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $41.5 million in Q1 2021 and troughed at $300000.0 in Q3 2022.
• A 5-year average of $8.2 million and a median of $5.8 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2021 and 2023: Net Equity Issued and Repurchased jumped 1578.41% in 2021, then tumbled 92.82% in 2023.
• Over 5 years, Net Equity Issued and Repurchased stood at $41.5 million in 2021, then sank by 85.42% to $6.0 million in 2022, then sank by 92.82% to $433901.0 in 2023, then jumped by 1168.93% to $5.5 million in 2024, then tumbled by 81.36% to $1.0 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $1.0 million, $6.8 million, and $5.5 million for Q4 2025, Q1 2025, and Q4 2024 respectively.